Table 4.
Univariate and multivariable analyses of progression-free survival.
| UVA | MVA | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| Age (years) | 1.09 | 1.01–1.18 | 0.034 | 1.02 | 0.93–1.12 | 0.791 |
| Sex (male vs. female) | 1.89 | 1.04–3.46 | 0.038 | 1.49 | 0.74–3.00 | 0.261 |
| ECOG (0 vs. 1–2) | 0.65 | 0.33–1.25 | 0.196 | |||
| ACE-27 (0–1 vs. 2–3) | 0.33 | 0.16–0.66 | 0.002 | 0.56 | 0.23–1.34 | 0.193 |
| Disease extent (BRPC vs. LAPC) | 1.24 | 0.69–2.23 | 0.476 | |||
| Tumor location (head vs. other) | 0.94 | 0.52–1.69 | 0.827 | |||
| Induction CT duration (>4 vs. ≤4 months) | 0.95 | 0.52–1.72 | 0.861 | |||
| Induction CT (mFFX vs. GnP) | 0.99 | 0.54–1.82 | 0.980 | |||
| Resected (yes vs. no) | 0.25 | 0.13–0.47 | <0.001 | 0.40 | 0.17–0.93 | 0.034 |
| Baseline CA 19-9 (U/mL) | 1.00 | 0.99–1.00 | 0.387 | |||
| Pre-SBRT CA 19-9 (U/mL) | 1.00 | 1.00–1.00 | 0.405 | |||
| Baseline Total Bilirubin (mg/dL) | 1.02 | 0.91–1.10 | 0.729 | |||
| Post-SBRT/surgery chemotherapy (yes vs. no) | 0.43 | 0.22–0.82 | 0.011 | 0.58 | 0.28–1.19 | 0.140 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ACE-27, adult comorbidity evaluation-27; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer; mFFX, modified FOLFIRINOX; GnP, gemcitabine plus nab-paclitaxel; CA 19-9, cancer antigen 19-9; SBRT, stereotactic body radiation therapy. Bold text indicates p-value < 0.05.